Clinical Profile and Patterns of Progression (PD) of Patients (PTS) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC) Treated with First Line Bevacizumab (B): Avva Study
| Autor: | Oscar Juan, Ramon Garcia-Gomez, Belen Saenz Rubio, María Sereno, Manuel Domine, S. Saura, J. de Castro, M. Cobo, Jose Maria Garcia-Bueno, E. Pujol |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Chemotherapy
education.field_of_study medicine.medical_specialty Bevacizumab business.industry medicine.medical_treatment Population Hematology medicine.disease Gastroenterology Clinical trial Oncology Tolerability Internal medicine Concomitant medicine Adenocarcinoma education Lung cancer business medicine.drug |
| Zdroj: | Annals of Oncology. 23:ix441 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/s0923-7534(20)33815-1 |
| Popis: | Background B in combination with platinum doublets prolongs survival and delays PD in chemo-naive pts with advanced nsNSCLC and its safety profile has been widely described in clinical trials. In this study we aim to evaluate the behavior, clinical profile and patterns of PD of real-life nsNSCLC pts treated with B in 44 Spanish institutions. Methods AVVA is a multicenter, epidemiological study to define the clinical profile (gender, age, PS, histology, stage, comorbidities, tumor load, Tx, response and tolerability) and describe the patterns of PD. Pts diagnosed with advanced nsNSCLC and evidence of PD after treatment (Tx) with standard chemotherapy (CT) plus B up to 6 cycles followed by maintenance B were included. Results Data of 158 pts are presented. Clinical profile was: median age 58 years (range 34-79); male 65%; stage IV 91%; adenocarcinoma 77%; ECOG PS 0/1/ ≥ 2 (%): 35/56/9; never/current/former smokers (%): 23/40/37. 64% of pts presented relevant concomitant disease at baseline (27% cardiovascular disease, 24% pulmonary disease). Tx received: B plus carboplatin-doublet/cisplatin-doublet/other (%) 70/25/5. Median no. of cycles for CT/B: 6/9. Patterns of PD: 44% presented high tumor load (tumor diameter ≥55mm and ≥5 lesions); 97% of pts presented intra-thoracic disease, 53% presented extra-thoracic disease and 13% only pulmonary disease. High tumor load was associated with extra-thoracic disease (p Conclusions B was effective in this real-life patients' population, irrespective of tumor load and location of the disease. These results confirm the well-established safety profile and the efficacy of B as frontline Tx in nsNSCLC. Disclosure All authors have declared no conflicts of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|